Skip to main content

Table 2 Trial construct 1—symptomatic trial. Power to detect an expected 2.60-point difference in ADAS-cog change in the planned sample (n = 360)

From: Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

Trial modification Linear mixed effects model: categorical time Linear mixed effects model: continuous time Student’s t test Original t test (for reference)
Scenario 1 .51 .35 .33 .80
Scenario 2 .89 .69 .72 .80
Scenario 3 .98 .85 .90 .80